Advanced Filters
noise

Uterine Cancer Clinical Trials

A listing of Uterine Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 508 clinical trials
Q Qin Xu

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the …

18 - 75 years of age Female Phase 2
A Anna Wilbanks

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.

18 years of age Female Phase 1
S Sheila Medina-Torne

Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy

The goal of this observational study is to learn more about the biology of cervical cancer in women who receive radiation therapy for this condition. The main question it aims to answer is: Does radiation therapy alter the expression of tissue factor and other molecules in cervical cancer over time? …

18 years of age Female Phase N/A

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer

18 years of age Female Phase 2
E Emilie Slanoc, RN

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

18 years of age Female Phase 2
D Dongling Zou, M.D.

The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.

18 - 75 years of age Female Phase N/A
N Nimmi Ramanujam, PhD

Pilot Study for Speculum Free Cervical Cancer Screening

The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.

21 - 65 years of age Female Phase N/A
M Marie Plante, M.D.

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior …

18 - 40 years of age Female Phase N/A
S Shaoxing Sun

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are: The efficacy of this combination in R/M/P CC; The tolerance of this combination in …

18 - 75 years of age Female Phase 2
M Meng Maobin M, MD

Serplulimab for Locally Advanced Cervical Cancer

This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).

18 - 75 years of age Female Phase 2

Simplify language using AI